Candel Therapeutics, Inc. (CADL): restructuring charge — Candel Therapeutics announces 50% workforce reduction, restructuring to focus on CAN-3110 and enLIGHTEN platform

Candel Therapeutics, Inc.

Approximately 50% workforce reduction; one-time restructuring charge of ~$0.7M in Q4 2023.
Cash runway extended into Q4 2024; company prioritizes CAN-3110 development and enLIGHTEN platform.
Key CAN-2409 readouts in 2024: NSCLC overall survival (Q2), pancreatic interim (Q2), prostate (Q4).
Company will explore partnering opportunities for CAN-2409 to reduce commercial manufacturing costs.
Initial CAN-3110 repeated injection data in recurrent high-grade glioma expected H2 2024; new enLIGHTEN data Q3 2024.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Candel Therapeutics, Inc. announced a restructuring with charges of approximately $0.7 million affecting the Company (approximately 50%).

Type: restructuring
Charge: approximately $0.7 million
Affected area: the Company
Headcount: approximately 50%

Exact text from the filing

On November 26, 2023, the Board of Directors (the “Board”) of Candel Therapeutics, Inc (the "Company") approved a strategic restructuring to focus on continuation and expansion of development of CAN-3110 as well as the enLIGHTEN TM Discovery Platform, and reducing the Company’s workforce by approximately 50%, as well as reducing expenses associated with enabling commercial readiness of CAN-2409, while maintaining and prioritizing key clinical readouts in 2024 (the “Restructuring Plan”). In connection with the Restructuring Plan, the Company estimates that it will incur a one-time restructuring charge of approximately $0.7 million in the fourth quarter of 2023 related to severance and healthcare and related benefits costs.

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Candel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-066248

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.